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Abstract
Mechanisms of resistance for HNSCC to cisplatin (CDDP), the foundational chemotherapeutic agent in the treatment of this
disease, remain poorly understood. We previously demonstrated that cisplatin resistance (CR) can be overcome by targeting
Trk receptor. In the current study, we explored the potential mechanistic role of the BDNF-TrkB signaling system in the
development of CDDP resistance in HNSCC. Utilizing an in vitro system of acquired CR, we confirmed a substantial up-
regulation of both BDNF and TrkB at the protein and mRNA levels in CR cells, suggesting an autocrine pathway
dysregulation in this system. Exogenous BDNF stimulation led to an enhanced expression of the drug-resistance and anti-
apoptotic proteins MDR1 and XiAP, respectively, in a dose-dependently manner, demonstrating a key role for BDNF-TrkB
signaling in modulating the response to cytotoxic agents. In addition, modulation of TrkB expression induced an enhanced
sensitivity of cells to CDDP in HNSCC. Moreover, genetic suppression of TrkB resulted in changes in expression of Bim, XiAP,
and MDR1 contributing to HNSCC survival. To elucidate intracellular signaling pathways responsible for mechanisms
underlying BDNF/TrkB induced CDDP-resistance, we analyzed expression levels of these molecules following inhibition of
Akt. Inhibition of Akt eliminated BDNF effect on MDR1 and Bim expression in OSC-19P cells as well as modulated
expressions of MDR1, Bim, and XiAP in OSC-19CR cells. These results suggest BDNF/TrkB system plays critical roles in CDDP-
resistance development by utilizing Akt-dependent signaling pathways.
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Introduction
As the sixth most common cancer worldwide, head and neck
squamous cell carcinoma (HNSCC) is responsible for 5% percent
of all cancers diagnosed in the United States [1]. The evolution of
treatment for this disease has progressed to a greater emphasis on
the use of cisplatin (CDDP)-based chemotherapy in the neoadju-
vant and adjuvant settings. However, the clinical response to
CDDP is associated with only a 10–15% improvement in local-
regional control of disease, and marginal improvement in overall
survival [2,3,4]. These sobering results suggest that resistance to
CDDP (CR) is a fundamental biological property of this disease.
Moreover, tumor recurrences or distant metastasis rarely respond
to CDDP-based regimens. Therefore, understanding the mecha-
nisms underlying CDDP resistance may provide strategic targets
and promising treatments against HNSCC.
Platinum-based chemotherapeutic agents, which include CDDP
and carboplatinum, function therapeutically primarily by inducing
DNA damage in rapidly dividing cells, thereby inducing apoptosis
and cell death. Various mechanisms have been reported to
contribute to the development of resistance against platinum-
based chemotherapeutic agents including: (1) increased drug
efflux; (2) decreased drug influx; (3) enhanced detoxification
through GST-p activation; (4) suppressed apoptosis; and (5)
enhanced DNA repair mechanisms [5,6]. Among these mecha-
nisms, the Tyrosine Receptor Kinase B and Brain Derived
neurotropic Factor (TrkB/BDNF) system has been reported to be
responsible for chemoresistance, through Akt/PI-3K and MAPK
signaling pathways, in selected models of cancer [7,8]. However,
TrkB-mediated resistance to CDDP has not been studied in
HNSCC. Although it is clearly evident that TrkB/BDNF system
plays a role in tumor progression and metastasis, the molecular
mechanisms underlying BDNF-induced chemoresistance develop-
ment are not fully understood.
The tropomyosin-related kinase B receptor (TrkB) belongs to
receptor tyrosine kinase family and triggers its intracellular signals
with its ligands, brain derived neurotrophic factor (BDNF) and
neurotrophin 4 (NT4). TrkB has been shown to be over-expressed
in various cancer types and is associated with poor prognosis
[9,10]. Cumulative evidence indicates TrkB is responsible for
tumor progression such as invasion, metastasis, angiogenesis, and
resistance against therapeutic agents [11,12,13]. Mechanistically,
the activation of TrkB by BDNF has shown to activate various
intracellular signaling pathways including Akt, Src, or MAPK
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human cancer [14,15]. While our previous studies have shown
that the resistance of HNSCC to CDDP-based therapy can be
overcome with inhibition of TrkB pathways, the mechanisms for
this phenomenon has yet to be elucidated [13].
In previous studies, we reported that both TrkB and BDNF
were overexpressed in HNSCC, and that modulation of TrkB
expression altered the invasive phenotype in this disease [9].
Moreover, we identified TrkB as a potential target for therapy in
CDDP-resistant HNSCC [13]. These findings led us to investigate
the mechanisms underlying CDDP-resistance induced through
BDNF\TrkB in HNSCC. In the current study, we demonstrate a
novel molecular mechanism of action for TrkB/BDNF in
modulating the response of HNSCC to cisplatin-based treatment,
primarily through differential apoptotic response. These results
provide a potential strategic approach for reversing cisplatin
resistance in aggressive HNSCC.
Materials and Methods
Cell lines and Reagents
The head and neck squamous carcinoma cell (HNSCC) lines
OSC-19 [9,13,16] , HN-5 [9,13], and UMSCC1 [13] cells were
maintained with DMEM supplemented with 2 mM L-glutamine,
0.1 mM MEM non-essential amino acids, 1 mM sodium pyruvate,
MEM vitamin solution 100 U/ml streptomycin, penicillin, vitamin
and 10% FBS as described previously. OSC-19 and HN-5 cell lines
were treated with low dose of cisplatin for six months to generate a
cisplatin resistant strains of both cell lines. For end-point PCR
analysis, PCR primer set for GAPDH (VHPS-3541) was purchased
from Real Time Primers (Elkins Park, PA, USA). Three AKT
siRNA oligo pairs (59 ‘CUCACAGCCCUGAAGUACU 39,5 9
AGUACUUCAGGGCUGUGAG 39;5 9 GAGACUGACAC-
CAGGUAUU 39,5 9 AAUACCUGGUGUCAGUCUC 39;5 9
GUGCCAUGAUCUGUAUUUA 39,5 9 UAAAUACAGAU-
CAUGGCAC 39) and a non-target universal negative control (59
GCGCGAUAGCGCGAAUAUATT 39,5 9 UAUAUUCGCG-
CUAUCGCGCTT 39) were purchased from Sigma-Aldrich (Saint
Louis, MO) to knock down AKT. A pool of the three AKT siRNA
oligos was used to knock down AKT. The following antibodies were
used for western blot analysis: goat anti-rabbit antibody (Santa
Cruz, sc-2004), goat ant-mouse antibody (sc- 2005); p-Akt(4058),
Akt1(2938), p-Src(2101), Src(2108), p-MAPK(9101), MAPK(9102),
Bim(2819), GST-p(3369), PARP(9532), Cleaved PARP(9541), and
BAX were from Cell Signaling (Danvers, MA); TrkB(sc-8316),
GSK-3b(sc-9166), and MDR1(sc-55510) were from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA); and GAPDH (AM4300,
Ambion, Austin, TX). Cisplatin and MTT purchased from Sigma
(St. Louis, Mo). An Akt inhibitor, triciribine (TCN) was obtained
from Berry Associates (Dexter, MI).
Western blotting (WB)
All western blotting analysis was performed as described
previously [17]. Briefly, five to fifty microgram of total protein
was loaded to 8 to 12% SDS-PAGE, and transferred onto PDVF
membrane. The membrane was blocked with 5% milk in TBST
and incubated with the appropriate primary and secondary
antibodies and developed with Lumi-Light Western Blotting
detection kit (Roche Applied Sciences, Indianapolis, IN). Densi-
tometry data were analyzed by using Un-Scan-It gel Software (Silk
Scientific Corp., Orem, UT) and statistical analysis was performed
by utilizing either conventional Student’s t test or ANOVA
followed by post hoc comparisons based upon modified Newman-
Keuls-Student procedure, where appropriate. Results are reported
as mean +/2 SEM. A p value of ,0.05 was considered significant
and all are paired and two-tailed.
Plasmid Transfections
Short-hairpin RNA (shRNA) constructs targeting TrkB (Cat.
TR320436, Origene, Rockville, MD) were introduced into cells via
retroviral infection or with lipofectamine2000 reagent according to the
manufacturer’s protocol, as previously described [16]. For TrkB over-
expression, pcDNA3.1 plasmids containing the full length cDNA
sequences for human TrkB was stably transfected into UMSCC1 cells
and selected with G418. TrkB expression was confirmed by SDS-
PAGE gel analysis and end-point RT-PCR analysis.
RT-PCR
Extraction of total RNAs was conducted by using the Qiagen
RNeasy Mini kit (Valencia, CA). The quality and quantity of
extracted RNA was analyzed by using Nanodrop (ND-1000)
spectrophotometer (NanoDrop Technologies, Inc., Wilmington,
DE) at the absorbance ratio of 260 and 280 nm. About 700 ng
RNA was used as the template for semi-quantitative RT-PCR
analysis to determine expression of TrkB at mRNA level. To
determine expression level of TrkB at HNSCC, we conducted
one-step RT-PCR reaction with SuperScriptH III One-Step RT-
PCR System with PlatinumHTaq (12574-026, Invitrogen, Carls-
bad, CA) with the Gene Amp PCR System 9700 (AB Applied
Biosystems, Carlsbad, CA), according to manufacturer’s instruc-
tion. For RT-PCR, the primers used were human TrkB 59 CCC
ACT CAC ATG AAC AAT GG 39 (forward) and 59 TCA GTG
ACG TCT GTG GAA GG 39 (reverse); human BDNF 59 AAA
CAT CCG AGG ACA AGG TG 30 (forward) and 59 AGA AGA
GGA GGC TCC AAA GG 39 (reverse); GAPDH (Real Time
Primers, Elkins Park, PA), 59 GAG TCA ACG GAT TTG GTC
GT 39 (forward) and 59 TTG ATT TTG GAG GGA TCT CG 39
(reverse). After a reverse transcription reactions at 55uC for
30 minutes, there was an initial 10-minute denaturation at 95uC
followed by the 40 cycles run consists of a 15-second denaturation
step at 94uC and an annealing step at 60uC for 30 seconds, and
extension step at 68uC for 1 minute. The density of bands was
determined by using Un-Scan-It gel Software (Silk Scientific
Corp., Orem, UT) and statistical analysis was performed by
utilizing either conventional Student’s t test. The PCR results were
averaged with three independent experiments, which were used in
the statistical analysis. Results were normalized to GAPDH.
Cell Proliferation Assay with MTT
To calculate IC50 of CDDP in various HNSCCs, MTT assay
was conducted. Fifteen hundred cells were seeded into each well of
96-well plates and cultured overnight. Cells were treated with
defined concentrations of CDDP for three days, followed by the
MTT assay. Briefly, 25 ul of 5 mg/ml MTT was added to each
well. After three hour incubation with MTT, the media was
removed carefully. The formed dye was dissolved with 100 ul
DMSO and the absorbance of each well was read using a micro-
plate reader. Six or eight samples were treated with same
concentration of CDDP. Experiments were repeated at least three
times. CDDP IC50 was calculated using the GraphPad Prism
Software (GraphPad Software, Inc.).
ELISA Assay
To determine expression level of BDNF, we performed ELISA
assay with BDNF EmaxH ImmunoAssay System (G7610, Promega,
Madison, WI) based on the manufacturer’s instructions. Briefly,
cells were cultured to 80% confluence followed by replacement of
BDNF Contributes to Cisplatin Resistance
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medium. This medium was centrifuged at 1000 g for 10 minutes
and used for determining BDNF concentration.
Immunohistochemistry
Tissues for immunochemistry were obtained from mice as
previously reported [16]. Immunohistochemistry was conducted
as previously described [17], using anti-XiAP (1:100, catalogue #
IMG-5770; IMGENEX, San Diego CA, USA), anti-Ki67 (1:50,
Dako,Carpinteria,CA,Catalogue# M7240),oranti-Bimantibody
(1:100, catalogue # 2933; Cell Signaling, Danvers, MA, USA).
Quantification of immuohistochemistry in mouse tumor
xenografts was done by counting positive cells in high power field
(2006) using Image-Pro MC 6.1 (Media Cybernetics, Inc.,
Figure 1. CDDP-resistant HNSCC showed up-regulation of TrkB and BDNF expression. A and B, IC50 values for parental cells and its
CDDP-resistant cells, OSC-19, A, and HN-5, B. Cell viability was measured by MTT assay 3-day after incubation with CDDP. Each point shows mean 6
SDE. IC50 values were calculated with the prism software form the GraphPad Software. C and D, Lysates from parental cells and its CDDP-resistance
cells were analyzed by western blot assay. After lysates were separated with 12% (BDNF) and 8% (TrkB) SDS-PAGE gels membrane was exposed to
proper antibodies. E. The expression levels of TrkB and BDNF were determined with OSC-19 parental (OSC-19P) and its CDDP-resistance cells (OSC-
19CR). Total RNA was extracted from both OSC-19P and OSC-19CR cells and RT-PCR was performed as described at materials and methods. Cloned
products were separated with 1% Agarose gel. F. After 24 hours cell culture, medium was collected and the concentration of BDNF was determined
with ELISA kit.
doi:10.1371/journal.pone.0030246.g001
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different tumors.
STR profile nalysis of parental and CDDP-Resistant cell
lines
Extraction of genomic DBA (gDNA) was conducted by using
Puregene Genomic DNA purification Kit (Gentra Systems, MN,
Minnesota) following instructions provided by the manufacturer.
The amount of extracted DNA was analyzed by using Nanodrop
(ND-1000) spectrophotometer (NanoDrop Technologies, Inc.,
Wilmington, DE). STR DNA fingerprinting analysis to determine
isogenecity between parental cells and chemoresistant cells at the
Characterized Cell Line Core (CCSG) of the MD Anderson
Cancer Center. Cell lines were validated by STR DNA
fingerprinting using the AmpF,STR Identifiler kit according to
manufacturer instructions (Applied Biosystems cat 4322288). The
STR profiles were compared to known ATCC fingerprints
(ATCC.org), to the Cell Line Integrated Molecular Authentication
database (CLIMA) version 0.1.200808 (http://bioinformatics.
istge.it/clima/) (Nucleic Acids Research 37:D925-D932 PMCID:
PMC2686526) and to the MD Anderson fingerprint database.
Results
TrkB is up-regulated in cisplatin-resistant head and neck
squamous carcinoma cell lines
We examined expression of TrkB and BDNF levels in cisplatin-
resistant head and neck squamous cell carcinoma cell lines (OSC-
19CR and HN-5CR, respectively), as previously described [13].
These CR cells were confirmed for their isogenic lineage by short
tandem repeat genotyping (STR, Table S1). The degree of CDDP
resistance was determined with the MTT assay, and long-term
exposure to CDDP induced a 3–4 fold increase in the IC50 of each
cell line. (Figure 1A & 1B). We next established that both TrkB
and BDNF expression was up-regulated in OSC-19CR and HN-
5CR cells, compared to the parental cell lines. These findings were
confirmed by ELISA and RT-PCR for BDNF and by western blot
and RT-PCR for the TrkB receptor (Figure 1C, 1D, 1E & F).
These results suggested that the chemoresistant phenotype were
associated with altered expression of BDNF-TrkB and confirmed
our prior results [9,13,16].
CDDP-resistant cells up-regulate an anti-apoptotic
expression profile
As our previous studies supported the notion that downstream
dysregulation in drug metabolism and enhanced apoptosis resis-
tance were associated with TrkB/BDNF signaling, we next
hypothesized that the observed CR phenotype was induced by
alterations in apoptotic pathways. Substantial upregulation of anti-
apoptotic proteins and suppression of pro-apoptotic proteins were
seen in the CR cell lines. In CDDP-resistant cells, XiAP, an
inhibitor of apoptosis, was up-regulated, while Bim, a pro-apoptotic
maker, was down-regulated. However, we failed to observe any
alteration of other apoptotic markers including Bax, Bid, Bok and a
slight down regulation in the basal expression of cleaved PARP in
the resistant cell lines (Figure 2A). In order to understand the
Figure 2. CDDP resistant cells modulate expression of molecules related with cell survival. A. Apoptotic molecules, B. Drug resistance-
related molecules, and C. intracellular signal molecules.
doi:10.1371/journal.pone.0030246.g002
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regulation of Cisplatin resistance, we analyzed the expression of
anti-apoptotic molecules of the BCL2 family and showed that BCL-
XL and Survivin were upregulated in the CDDP-resistant cell lines
compared to their parental counterparts (Figure S1A).
Among the enzymes associated with drug resistance, increased
expression of multidrug resistance 1 (MDR1), and glutathion S
tranferase-p (GST-p) was noted (Fig. 2B), which confirmed our
previous findings vis-a `-vis the role of KiSS1 in mediating CR
behavior, and is consistent with previous findings of GSK3b-
mediated TrkB-induced cell protection from chemotherapy
[16,18]. To determine whether downstream signaling in known
pathways of apoptosis resistance was associated with these
findings, we next compared the activation of intracellular cascades
in the parental and CR cells. While MAPK phosphorylation was
consistently elevated among the resistant cell lines, increased Src
and Akt phosphorylation was also observed, suggesting that these
selected pathways coordinated CDDP metabolism and the
resulting inhibition of cell death in the presence of CDDP (Fig. 2C).
CDDP induces differential signaling in CDDP resistance
As our previous data supported the concept that activation of
anti-apoptotic proteins was partially driven by BDNF in drug-
sensitive cells, we explored whether this phenomenon was
differentially altered in the drug-resistant cell lines. First, to
examine the impact of CDDP treatment on TrkB expression, we
compared the parental cells to the resistant cells for receptor
expression. Western blot analysis revealed that after 24 hours of
exposure to CDDP, a substantial increase in receptor expression
was seen in the sensitive cells (125% increase), but a blunted
response was noted in the CR cells due to elevated basal levels
(25% increase) (Figure 3A). However, we observed an induction of
pro-survival pathways in the CR cells, as evidenced by
phosphorylation of MAPK (50% increase) and Akt (30% increase),
while baseline Src activation remained elevated (Figure 3B). The
results were consistent with our previous findings when comparing
the basal activity of anti-apoptotic pathways in the parental and
resistant lines. Additionally, CDDP induced genes favoring cell
death in the parental cells, particularly the pro-apoptotic molecule,
Bim. Treatment of CDDP resistant cell line with a relatively high
dose of CDDP for 24 hrs did not alter the basal expression of
XIAP and MDR1 suggesting a stable phenotypic change of these
molecules in response to drug treatment (Figure 3C). It is
interesting to note that, overall, CDDP-resistant cell lines have
an elevated level of STAT3 phosphorylation, but no change is
observed when cells are treated with CDDP suggesting that
STAT3 may not be playing a significant role in the development
of resistance in Head and Neck cell lines (Fig. 3B). These results
demonstrate that CDDP resistant cell lines harbor a differential
molecular response profile that may be due in part to enhanced
pro-survival signaling and constitutive apoptotic resistance.
BDNF regulates signaling and apoptosis in drug-sensitive
HNSCC
We next sought to determine whether exogenous BDNF could
induce the molecular alterations that were consistent with those
Figure 3. Differential response of OSC-19P and OSC-19CR to CDDP. Cell lysate was collected following 5 uM of CDDP and separated with
SDS-PAGE gel. Membrane was then incubated with indicated antibodies. A. Expression of TrkB was determined in both OSC-19P and OSC-19CR
following 5 uM of CDDP treatment. B. Phosphorylation of Akt, Src, MAPK, and STAT-3 was determined following 5 uM CDDP treatment. Levels of
phosphorylated kinases were normalized with expression of total kinases. C. 5 uM of CDDP modulates expression of Bim, XiAP, and MDR1. Expression
levels of Bim, XiAP, and MDR1 were determined by Western blot analysis.
doi:10.1371/journal.pone.0030246.g003
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BDNF signaling impacted the induction of apoptotic pathways in
CDDP-sensitive cell lines, we analyzed the alterations in the
phosphorylation status of various signaling molecules. After
exposure to BDNF for 24 hours, stimulation with BDNF resulted
in increased phosphorylation of various kinases, Akt, Src, and
MAPK in parental cells, consistent with previous studies regarding
its role in tumor proliferation and apoptosis (Figure 4A) [13]. The
activation of these kinases was noted in a dose-dependent manner,
even at low BDNF concentrations. We also measured expression
levels of XiAP, Bim, and MDR1, which were previously found to
be dysregulated in our system. In these experiments, we found that
level of XiAP, an inhibitor of apoptosis, was induced by a 5.3-fold
change under the influence of BDNF exposure (Figure 4B). In
contrast, the expression of the pro-apoptotic protein Bim was
reduced by 70% in a dose-dependent manner after exposure to
BDNF (Figure 4B). In line with these findings, the expression of
MDR1, the cisplatin-efflux complex was enhanced by 60% when
cells were exposed to BDNF (Figure 4B). These results suggests
that exposure to exogenous BDNF could contribute to a molecular
profile that mimicked the CDDP-resistant one.
Alterations in CDDP-response is mediated by TrkB
Although the previous results highlighted an association
between CDDP resistance and enhanced TrkB signaling, we next
sought to test whether this relationship was directly mediated by
receptor activity. Initially, we over-expressed TrkB in the low-
expressing UMSCC1 cell line and compared the response of these
genetically-altered cells to CDDP. A moderate induction of CDDP
resistance was noted (Figure 5A & 5B) in cells with genetically
upregulated TrkB, compared to those transfected with an empty
vector, confirming our prior results [13]. As shown in Figure 5A,
over-expression of TrkB increased in the IC50 from 1.2 uM (empty
vector) to 2.3 uM significantly (p,0.05). Corresponding to this
altered phenotype, we observed that Bim was down-regulated,
suggesting that the CDDP resistance may have been due in part to
suppressed apoptosis through a TrkB-directed mechanism
(Figure 5C). Additionally, we found that the expression of
MDR1 and XiAP were induced by genetic upregulation of TrkB,
a finding that was in line with our results from exogenous BDNF
exposure. To further establish this direct link, we genetically
suppressed the expression of TrkB HNSCC cell lines with high
levels of endogenous TrkB, HN-5 and OSC-19. In contrast to the
previous experiments, the relative loss of TrkB expression initiated
a more cisplatin sensitive response in HNSCC cells, with a nearly
66% reduction in IC50 value in the TrkB-knockdowns (Figures 5D
and S1B). Additionally, when shRNA-based knockdown of TrkB
was induced, an inverse expression change between Bim and
MDR1 was seen, which was complementary to the TrkB
overexpression results. Corresponding analysis by Western blotting
of MDR1 expression revealed attenuated expression, and a
reciprocal enhancement in Bim expression (Figure 5E). These
findings correlated not only with the previous TrkB inhibition
experiments providing greater evidence for a direct role of BDNF-
TrkB in modulating therapy resistance in HNSCC. An interesting
observation was that knock down of TrkB led to reduced BDNF
expression, suggesting a possible autocrine pathway for BDNF/
TrkB in in the development of CDDP-resistance in HNSCC. In
addition inhibition of TRKB in CDDP-resistant cell line increased
Figure 4. BDNF induces signals and modulates MDR1, Bim, and XiAP in CDDP sensitive cells. A. Dose-dependent up-regulation of
intracellular signals, Akt, Src, and MAPK in OSC-19P. The culture reaches ,80% confluent, cells were starved for overnight with medium without
serum. Lysate was collect after 24 hour treatment with 100 ng/ml BDNF and separated with SDS-PAGE gel and membrane was incubated with
indicated antibodies. B. Western blot analysis of XiAP, Bim, and MDR1 following treatment with various concentration of BDNF for 24 hours (0.1, 1, 10,
and 100 ng/ml, respectively).
doi:10.1371/journal.pone.0030246.g004
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resistant cell line (Figure S1C).
Akt plays a crucial role in TrkB-induced CDDP-resistance
development
We next explored the intracellular signaling pathways that were
responsible for mediating TrkB-induced CDDP resistance devel-
opment in our system. We exposed CR cells to an inhibitor of Akt
signaling and assayed for the expression of Bim, XiAP and MDR1
(Figure 6). Selective Akt pathway abrogation led to specific
induction of Bim expression, and a significant decrease in MDR1
and XiAP protein expression, as determined by WB analysis. The
changes in expression levels of MDR1, XiAP, and Bim in OSC-
19CR cells reverted to the levels noted in the parental cells
(Figure 6A). We further substantiated these findings with genetic
suppression of Akt prior to BDNF exposure. While a non-targeted
construct did not alter the expected changes in Bim, MDR1 and
XiAP expression, siRNA targeting Akt selectively blocked the
BDNF-regulated alteration in apoptosis and drug resistance
regulation (Figure 6B). Taken together, these results strongly
support our hypothesis that up-regulation of TrkB/BDNF system
contributes to CDDP-resistance development through modulating
molecules, such as MDR1 and XiAP through Akt-dependent
pathway facilitating cell survival against CDDP in HNSCCs.
Expression of Bim and Ki-67 in animal models of HNSCC
To determine whether our in vitro findings were relevant in
animal models of HNSCC, we analyzed the expression level of
Bim, XiAP, MDR1, and Ki-67 in vivo (Figure 7A–C). Mouse-borne
tumors derived from parental or CR cell lines were assayed by
immunohistochemistry [17]. We confirmed that Bim expression
was down-regulated in CDDP-resistant OSC-19CR tumors (48%),
compared to the parental tumors. In addition, protein expression
of XiAP and Ki-67 expression was increased in CDDP-resistant
OSC-19CR tumors (98% and 270%, respectively). However, we
failed to show significant up-regulation of MDR1 expression. (data
not shown). These data corroborated our hypothesis that
chemoresistant tumors were associated with biological markers
of apoptotic resistance and enhanced proliferative capacity [16].
Discussion
Our previous study has shown that the BDNF-TrkB signaling
axis contributes to tumor invasion and progression of HNSCC in
xenograft animal models [9]. In continuation of our studies, we
explored the role of this neurotrophic signaling axis in the
development of chemotherapy resistance in HNSCC. Phenotypic
characterization of cisplatin-resistant HNSCC cell lines demon-
strated an upregulation of both TrkB and its ligand, brain derived
neurotrophic factor (BDNF) with a concomitant increase in cell
proliferation and apoptosis. Utilizing over-expression and knock-
down experiments, we demonstrated the potential for the BDNF-
TrkB as a realistic target in overcoming therapy resistance in
HNSCC.
Various mechanisms of drug resistance have been identified
across differing cancer cell types. One major mechanism that has
been identified is enhanced resistance to the induction of apoptosis
Figure 6. Akt plays a critical role in TrkB-induced CDDP-resistance development. A. OSC-19CR cell lysate following treatment with 5 uM of
TCN, an Akt inhibitor, was collected and separated with SDS-PAGE to determine expression levels of Bim, XiAP, and MDR1. B. Expression levels of Bim,
XiAP, and MDR1 were determined with cell lysate following transfected with siRNA against role of Akt in CDDP-resistance development in HNSCC.
doi:10.1371/journal.pone.0030246.g006
Figure 5. TrkB altered sensitivity to CDDP in HNSCC. A. UMSCC1 cells were transfected with a vector containing wild-type TrkB (TrkB) or an
empty vector (EV). Cells were then exposed to CDDP for addressing increasing resistance of TrkB over-expressed UMSCC1 to CDDP. MTT cell viability
assay was conducted to determine the IC50 values. B. expression efficacy was confirmed by Western Blot analysis. BDNF expression level was also
determined. C. Expression levels of XiAP, Bim, MDR1, GST-p, and N-cadherin were determined with over-expressed UMSCC1 cells. Both OSC-19 and
HN-5 cells were stably transfected with a short-hairpin RNA construct targeting TrkB (TrkB shRNA) or a non-targeting, short-hairpin RNA construct (NT
shRNA). D. Both HN-5P and HN-5CR cells were then treated with various concentration of CDDP and analyzed to address the effect of TrkB down-
regulation on sensitivity to CDDP by suppressing TrkB expression. E. Down-regulation of TrkB expression was confirmed by Western blot analysis. Cell
lysates of suppressing TrkB were separated with SDS-PAGE and membrane was incubated with BDNF, Bim, XiAP, and MDR1 antibodies. Expression
levels of TrkB, BDNF, Bim, XiAP, and MDR1 were normalized with GAPDH.
doi:10.1371/journal.pone.0030246.g005
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changes in XiAP and Bim expression in the resistant cell lines,
compared to the sensitive parental cell lines. Moreover, these
changes were induced with exogenous BDNF treatment in the
parental cell lines. This evidence indicates that the modulation of
both XiAP and Bim expression is due, in part, to up-regulation of
BDNF/TrkB system in the CR system. As an inhibitor of
apoptosis, XiAP over-expression is a well-described phenomenon
in various types of cancer and appears to protect cells from various
insults [19]. This occurs through the inhibition of caspase
enzymes, which initiate and execute apoptosis [19]. As a pro-
apoptotic molecule, Bim has been demonstrated to induce
apoptosis by inhibiting anti-apoptotic molecules such as bcl-2,
bcl-xL, or bcl-w [20]. In the current study, we showed that Bim
expression was reduced in CDDP-resistant HNSCC and exoge-
nous administration of BDNF resulted in reduced Bim expression,
a finding that is consistent with effects seen in various disease
models including neuroblastoma model [18,21]. The increase in
BDNF can cause in part of Bim degradation through a MAPK-
dependent mechanism [18,21], although this phenomenon has not
been evaluated in our system. These findings suggest that down-
regulation of Bim by BDNF might be a potential mechanism
underlying CDDP-resistance development in the HNSCC. In
contrast to our findings, however, Li et al. (2007) reported that
reduction in Bim expression through BDNF failed to block the
CDDP-induced cell death in a neuroblastoma model [18]. This
indicated that perhaps Bim does not play a central role in drug
resistance in neuroblastoma, or alternatively, the acquired
resistance in our model mechanistically is driven by a direct
BDNF-Bim pathway. Further studies will be necessary to elucidate
Figure 7. Immunohistochemistry staining of mouse tumor tissue originated from OSC-19P and OSC-19CR. A. Immunohistochemistry
staining of OSC-19P (left) and OSC-19CR (right) with Bim. B. IHC staining of OSC-19P (left) and OSC-19CR (right) with Ki-67. The pictures were taken at
1006magnification, the inlet at 506magnification. (C) IHC staining of OSC-19P (left) and OSC-19CR (right) with XiAP.
doi:10.1371/journal.pone.0030246.g007
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BDNF in our system. One interesting result regarding the reduction
in Bim expression mediated by BDNF is that Bimhas been reported
to regulate anoikis, apoptosis induced by detachment, in various
cancers [22,23]. Another confounding issue is distinguishing the
anti-apoptotic roles of BDNF in anoikis resistance, as opposed to its
import in chemotherapy resistance [24,25].
Resistance to many common anticancer drugs, particularly
platinum-based agents, often occurs due to enhanced expression of
MDR1 [26], which encodes a P-glycoprotein, calcium-dependent
efflux pump. [27,28,29]. MDR1 expression has been reported in
various types of chemoresistant tumor phenotypes including
neuroblastoma, hepatoblastoma, ovarian cancer, and prostate
cancer [30]. Epigenetic changes in methylation of its promoter
region has been suggested as a mechanism to modulate MDR1
expression [31]. Although change in mRNA stability can
contribute to MDR1 expression [32] epigenetic methylation of
promoter for MDR1 gene has also been suggested to be a critical
mechanism in MDR1 expression at the transcription level and to
be associated with poor prognosis in various cancers [33,34,35,36].
In line with our studies, BDNF was shown to induce MDR1
expression in TrkB-overexpressing neuroblastoma cells, at the
transcriptional level [37]. These results suggest a possible
mechanism underlying up-regulation of MDR1 by TrkB/BDNF
through change in both transcription rate and mRNA stability in
CDDP-resistant HNSCC.
It is well known that BDNF utilizes PI-3K/Akt, MAPK, and Src
signaling pathways to induce various physiological functions
including anti-apoptosis and cell proliferation, angiogenesis, anoikis
and metastasis [9,13,14,38]. The results of current study also
revealed that activation of TrkB by BDNF was enhanced in the CR
cell lines, and led to robust induction of the Akt, MAPK, and Src
signaling pathways that exceeded the effects in the parental lines.
Because Akt is a central node in BDNF signaling and its
downstream effects [21,39,40,41], we focused on the contribution
of Akt in the development of CDDP resistance. Although we cannot
entirely exclude the relevanceof MAPK and Src here, our results do
not support major roles for these pathways in acquired chemore-
sistance. Modulation of XiAP and MDR1 expression by BDNF was
blocked by both pharmacological and genetic modulation of Akt,
suggesting that Akt is responsible for BDNF-induced apoptotic
resistance in HNSCC models. In distinction to this, Akt inhibition
failed to modulate the BDNF-regulation of Bim expression, perhaps
indicated that a bypass mechanism exists for Bim regulation
through TrkB. Previously, BDNF-induced BIM down-regulation
was found not to be an Akt-dependent effect, but rather a MAPK-
dependent pathway [18,21]. However, the Akt pathway was
reported to regulate Bim expression negatively by modulating
Forkhead transcription factor in nerve growth factor depravation
[42,43]. This may explain the observed enhancement in Bim
expression under conditions of Akt inhibition in the CR cells lines.
Further studies are necessary to distinguish the impact of BDNF on
the differential regulation of anti-apoptotic systems in HNSCC as it
pertains to the regulation of chemotherapy response. Perhaps
tumors that have a more ‘‘Akt-like’’ phenotype would be resistant to
CDDP-based therapy, a biological behavior that could be reversed
with dual BDNF-Akt inhibition.
In conclusion, our findings reveal novel regulatory mechanisms
for chemotherapy resistance directed in part by BDNF-TrkB axis in
a model of therapy resistant HNSCC. In the current study, we
found: (1) both TrkB and BDNF were up-regulated in CDDP
resistant HNSCC cell lines (2) a molecular phenotype consistent
with apoptotic resistance was associated with acquired CDDP
resistance expression (3) exogenous BDNF can induce a CDDP-
resistance in CDDP-sensitive cells (4) modulation of TrkB
expression resulted in XiAP, Bim, and MDR1 dysregulation, which
contributed to CDDP resistance (5) a phenotype that was driven in
part by dysfunction Akt signaling mediates CDDP resistance in
HNSCCs. Taken together, we have demonstrated a BDNF-TrkB
mediated mechanism that underlies CDDP resistance development
in HNSCC. These findings may provide insights into potential
molecular-based approaches to re-introduce chemotherapy sensi-
tivityintumorsthathavedevelopedacquired resistanceinHNSCC.
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